Achillion Sends HBV, HIV Treatment Elovucitabine To China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Achillion announced Feb. 1 it has outlicensed elvucitabine, its compound for hepatitis B virus and human immunodeficiency virus, to GCA Therapeutics in China